Neonatal alloimmune thrombocytopenia.
Neonatal alloimmune thrombocytopenia (NAIT) can occur when a mother is immunized against fetal platelet antigens inherited from the father. Early diagnosis and appropriate platelet transfusion therapy are essential to prevent life-threatening intracranial hemorrhage in the thrombocytopenic fetus or neonate. Five major human platelet antigen (HPA) systems are capable of causing this disorder with HPA-1a indicated most frequently. This article reviews the pathophysiology, clinical aspects, and management of NAIT. We also present our experience with treatment of neonates affected with this disorder.
Rothenberger
Sandra
S
Department of Pathology, Indiana University Hospital, Indianapolis, Indiana 46202, USA.
D016824:Antigens, Human Platelet / Q000276:immunology*; D001787:Blood Group Incompatibility / Q000276:immunology / Q000628:therapy; D000939:Epitopes; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D039661:Integrin beta3; D017713:Platelet Transfusion; D011247:Pregnancy; D013921:Thrombocytopenia / Q000276:immunology / Q000628:therapy
D016824:Antigens, Human Platelet; D000939:Epitopes; C061248:ITGB3 protein, human; D039661:Integrin beta3